Cancer drug Yondelis under FDA scrutiny

07/14/2009 | Reuters · Google

The FDA plans to ask a panel of experts to evaluate the accuracy of a study of Johnson & Johnson and Zeltia's Yondelis after the agency's staff found discrepancies in radiology readings. J&J unit Ortho Biotech is seeking to launch Yondelis as a combination treatment with another J&J cancer drug, Doxil, for women with recurring ovarian cancer.

View Full Article in:

Reuters · Google

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
Boise, ID